文献速递糖尿病肥胖与代谢综合征

司美格鲁肽在透析启动后的安全性:个体水平汇总分析

Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究为四项随机安慰剂对照试验的事后汇总分析,评估透析启动后继续使用司美格鲁肽的安全性。在307例启动透析的受试者中,165例继续用药(司美格鲁肽71例,安慰剂94例);司美格鲁肽组严重不良事件比例45% vs 57%,MACE事件率9.7 vs 16.1/100人年,全因死亡率13.8 vs 18.1/100人年。结论认为透析启动后继续司美格鲁肽似乎安全,但需更多证据。

要点

  • 透析启动后继续司美格鲁肽者严重不良事件比例45%,安慰剂组57%。
  • 司美格鲁肽组MACE事件率9.7/100人年,安慰剂组16.1/100人年。
  • 司美格鲁肽组全因死亡率13.8/100人年,安慰剂组18.1/100人年。

核心结论

  • 透析启动后继续使用司美格鲁肽似乎安全,但需更多证据,且其减少MACE和死亡的效果尚待验证。

研究设计与样本

  • 四项随机安慰剂对照试验(SUSTAIN-6、SELECT、FLOW、SOUL)的事后汇总分析,共34,064例随机受试者中307例启动透析,165例继续用药(司美格鲁肽71例,安慰剂94例)。

主要发现

  • 透析启动后,司美格鲁肽组严重不良事件32/71(45%),安慰剂组54/94(57%)。
  • 永久停用试验药物比例司美格鲁肽组8.5%,安慰剂组10.6%。
  • MACE事件率司美格鲁肽组9.7/100人年,安慰剂组16.1/100人年。
  • 全因死亡率司美格鲁肽组13.8/100人年,安慰剂组18.1/100人年。

临床怎么用

  • 对于已启动透析且仍在用药的2型糖尿病或肥胖患者,可考虑继续司美格鲁肽,但需个体化评估并监测不良事件。

局限性

  • 为事后分析,继续用药亚组样本量小(165例),事件数有限,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: People receiving dialysis are at high risk of cardiovascular and all-cause mortality. Semaglutide reduces major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) and those without T2D with obesity and high cardiovascular risk. Data to establish safety and efficacy in dialysis-dependent kidney failure are scarce. We aimed to assess the safety of semaglutide in people who initiate dialysis. RESEARCH DESIGN AND METHODS: In this post hoc analysis of four randomized, placebo-controlled trials (Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes [SUSTAIN-6], Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity [SELECT], Evaluate Renal Function With Semaglutide Once Weekly [FLOW], and Semaglutide Cardiovascular Outcomes [SOUL]), we evaluated systematically collected adverse events (AEs) from participants who initiated dialysis during study follow-up. We compared the proportion and event rates of systematically collected serious AEs (SAEs), including adjudicated MACE, and AEs leading to permanent treatment discontinuation in participants originally randomized to semaglutide or placebo who remained on treatment after dialysis initiation. RESULTS: Among 34,064 participants randomized across the trials, 307 initiated dialysis, of whom 165 participants randomized to semaglutide (n = 71) or placebo (n = 94) remained on treatment. After dialysis initiation, SAEs were reported in 32 of 71 (45%) and 54 of 94 (57%) participants, and the proportion of participants who permanently discontinued trial medication was 8.5% and 10.6% in the semaglutide and placebo groups, respectively. The MACE event rates were 9.7 and 16.1 events per 100 person-years, and all-cause mortality event rates were 13.8 and 18.1 events per 100 person-years, in the semaglutide and placebo groups, respectively. CONCLUSIONS: Although more evidence is needed, continuation of semaglutide after dialysis initiation appears safe and warrants efficacy testing regarding reduction in MACE and death.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Klein KR, Menacher A, Buse JB, et al. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. Diabetes Care. 2026. PMID: 41893299. doi:10.2337/dc26-0112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。